samedan logo
 
 
 
spacer
home > ebr > winter 2017 > capacity for success
PUBLICATIONS
European Biopharmaceutical Review

Capacity for Success

The global bioprocessing industry is growing rapidly, with more than 1,300 companies generating a staggering combined annual revenue of over $200 billion (see full pdf). Progress has been driven by the widely recognised benefits of biopharmaceutical products, including increased effectiveness, fewer side effects and the likelihood of them serving as disease cures rather than just treatment solutions to ease symptoms. Worldwide, the evolution of the bioprocessing industry has triggered the development of innovative technologies that facilitate the use of living cells and tissues for a range of pharmaceutical and clinical applications.

As such, bioprocessing – or bioproduction – has come to involve all current Good Manufacturing Practice (cGMP) employed in the development, scale-up and manufacture of biomolecular and cellular products, including monoclonal antibodies, vaccines, therapeutic proteins and cell-based therapies. In recent years, mammalian cells have been found to produce proteins with the correct conformations and post-translational modifications for the development of safe and effective treatments. In response, there has been a notable shift of the bioprocessing industry towards the use of mammalian cells for the manufacture of 55% of biopharmaceuticals (see full pdf).

The typical bioprocessing workflow is split into three stages – namely upstream processing, harvesting and downstream processing. During upstream processing, cells are grown in a controlled environment and scaled up to create maximum cell and protein concentrations with optimal target product profiles. Harvesting subsequently involves the removal of cells, cell debris and other such particulate matter from the product solution, before proceeding with downstream purification of the final product.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ileana Place, PhD, is Global Product Manager of Large Capacity Centrifuges at Thermo Fisher Scientific. She holds both a Master’s degree and a doctorate in Chemistry, and has used her previous experience as a scientist in academia and industry to bring innovative equipment solutions to the lab.
spacer
Ileana Place
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement